Table 2. Univariate regression analysis of 15-month costs (log-scale).
| Coefficient | Exp(coeff) | s.e. | P-value | |
|---|---|---|---|---|
|
Breast cancer | ||||
| Age | −0.015 | 0.985 | 0.004 | <0.001 |
| IMD ⩾3 | 0.064 | 1.066 | 0.093 | 0.491 |
| HER2 positive | 0.1454 | 1.157 | 0.083 | 0.082 |
| HR positive | −0.2032 | 0.816 | 0.089 | 0.024 |
| Lymph node positive | 0.5516 | 1.736 | 0.089 | <0.001 |
| Grade 3 | 0.520 | 1.682 | 0.100 | <0.001 |
| EQ-5D (at T1) | −1.020 | 0.361 | 0.363 | 0.006 |
|
Colorectal cancer | ||||
| Age | −0.0135 | 0.987 | 0.027 | 0.006 |
| Gender (female) | 0.1178 | 1.125 | 0.399 | 0.139 |
| IMD ⩾3 | 0.1202 | 1.128 | 0.190 | 0.53 |
| Dukes stage C | 0.5291 | 1.697 | 0.173 | 0.003 |
| EQ-5D (at T1) | −0.202 | 0.817 | 0.246 | 0.413 |
|
Prostate cancer | ||||
| Age | −0.0097 | 0.990 | 0.420 | 0.012 |
| IMD ⩾3 | −0.1033 | 0.902 | 0.179 | 0.566 |
| Gleason score ⩾7 | 0.4834 | 1.622 | 0.179 | 0.008 |
| EQ-5D (at T1) | −0.433 | 0.649 | 0.448 | 0.336 |
Abbreviations: Exp(coeff)=Expected value of the coefficient; HER2=human epidermal growth factor receptor 2; HR=hormone receptor; IMD=Index of Multiple Deprivation.